These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 31274613)
1. Favorable Response After Only One Cycle of Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE in a Patient With Metastatic Merkel Cell Carcinoma. Moghadam SZ; Divband G; Shakeri S; Aryana K Clin Nucl Med; 2019 Aug; 44(8):650-652. PubMed ID: 31274613 [TBL] [Abstract][Full Text] [Related]
2. Favorable Response of Metastatic Merkel Cell Carcinoma to Targeted 177Lu-DOTATATE Therapy: Will PRRT Evolve to Become an Important Approach in Receptor-Positive Cases? Basu S; Ranade R J Nucl Med Technol; 2016 Jun; 44(2):85-7. PubMed ID: 26471333 [TBL] [Abstract][Full Text] [Related]
3. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation. Jois B; Asopa R; Basu S Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668 [TBL] [Abstract][Full Text] [Related]
4. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics. Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215 [TBL] [Abstract][Full Text] [Related]
5. Combined Adnan A; Basu S J Nucl Med Technol; 2020 Sep; 48(3):292-294. PubMed ID: 32358042 [TBL] [Abstract][Full Text] [Related]
7. The efficacy of Zhang J; Song Q; Cai L; Xie Y; Chen Y J Cancer Res Clin Oncol; 2020 Jun; 146(6):1533-1543. PubMed ID: 32281025 [TBL] [Abstract][Full Text] [Related]
8. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE. Parghane RV; Talole S; Prabhash K; Basu S Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500 [TBL] [Abstract][Full Text] [Related]
9. Hepatopulmonary Shunt Reduction With 177Lu-DOTATATE Therapy. Acar E; Çapa Kaya G; Durak H Clin Nucl Med; 2016 Nov; 41(11):866-871. PubMed ID: 27607172 [TBL] [Abstract][Full Text] [Related]